Thiazolidinediones: Antidiabetic agents with effects on bone

Joint Bone Spine

Volumn 76, Issue 3, 2009, Pages 221-223

  Debiais, Françoise ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Osteoblasts; Osteoporosis; Peroxisome proliferator activated receptor gamma; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE TURNOVER; DRUG EFFECT; EDITORIAL; FRACTURE; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; OVARY POLYCYSTIC DISEASE; SIDE EFFECT;

AGED; ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; THIAZOLIDINEDIONES;

EID: 67349237782     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.01.005     Document Type: Editorial

References (20)

1. Grey A., Bolland M., Gamble G., et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomised, controlled trial. J Clin Endocrinol Metab 92 (2007) 1305-1310
2. Berberoglu Z., Gursoy A., Bayraktar N., et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92 (2007) 3523-3530
3. Glintborg D., Andersen M., Hagen C., et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomised, placebo-controlled trial. J Clin Endocrinol Metab 93 (2008) 1696-1701
4. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91 (2006) 3349-3354
5. Kahn S.E., Zinman B., Lachin J.M., et al., for the A Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes. An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31 (2008) 845-851
6. Meier C., Kraenzlin M.E., Bodmer M., et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 168 (2008) 820-825
7. Yaturu S., Bryant B., and Jain S.K. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30 (2007) 1574-1576
8. Rzonca S.O., Suva L.J., Gaddy D., et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 (2004) 401-406
9. Soroceanu M.A., Miao D., Bai X.-Y., et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183 (2004) 203-216
10. Ali A.A., Weinstein R.S., Stewart S.A., et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 (2005) 1226-1235
11. Lazarenko O.P., Rzonca S.O., Hogue W.R., et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148 (2007) 2669-2680
12. Jennermann C., Triantafillou J., Cowan D., et al. Effects of thiazolidinediones on bone turnover in the rat. J Bone Miner Res 10 (1995) S241
13. Sottile V., Seuwen K., and Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75 (2004) 329-337
14. Lecka-Czernik B., Gubrij I., Kajkenova O., et al. Inhibition of osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-γ. J Cell Biochem 74 (1999) 357-371
15. Lafage-Proust M.H., Thomas T., Guignandon, et al. Cell plasticity of osteoprogenitors. Joint Bone Spine 74 (2007) 536-539
16. Lecka-Czernik B., and Suva L.J. Resolving the two "bony" faces of PPARγ. PPAR Res 27489 (2006) 1-9
17. Okazaki R., Toriumi M., Fukumoto S., et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140 (1999) 5060-5065
18. Schwab A.M., Granholm S., Persson E., et al. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology 146 (2005) 4349-4361
19. Lazarenko O.P., Rzonca S.O., Suva L.J., et al. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38 (2006) 74-84
20. Lecka-Czernik B., Ackert-Bicknell C., Adamo M.L., et al. Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148 (2007) 903-911